Literature DB >> 32483525

A fatal case of COVID-19 due to metabolic acidosis following dysregulate inflammatory response (cytokine storm).

Shabnam Chhetri1, Faryal Khamis1, Nenad Pandak1, Huda Al Khalili2, Elias Said3, Eskild Petersen4.   

Abstract

The ongoing outbreak of COVID-19 has been expanding worldwide. As of 17 April 2020, the death toll stands at a sobering 147,027 and over two million cases, this has been straining the health care systems all over. Respiratory failure has been cited as the major cause of death but here we present a case about a patient who instead succumbed to severe metabolic acidosis with multiple organ failure.
© 2020 The Authors.

Entities:  

Keywords:  COVID-19; Cytokine storm syndrome; Metabolic acidosis

Year:  2020        PMID: 32483525      PMCID: PMC7236721          DOI: 10.1016/j.idcr.2020.e00829

Source DB:  PubMed          Journal:  IDCases        ISSN: 2214-2509


Introduction

The world is in the middle of a pandemic with a new coronavirus, SARS-CoV-2, which has a high mortality in the elderly and people with co-morbidities such as hypertension, chronic heart disease and diabetes. The clinical course is biphasic [1], first a viral infection in the upper or/and lower respiratory tract sometimes followed by a dysregulated inflammatory response (“cytokine storm”) with severe inflammation in the lungs which often require several weeks of mechanical ventilation. It is unclear what triggers the dysregulated inflammatory response which is a clinical feature much more commonly seen than in severe influenza pneumonia, and one suggestion is that it is the viral interaction with its human receptor, the acetylcholinesterase2, ACE2, molecule that could be an explanation [2]. A characteristic of the SARS-CoV-2 infection is lymphopenia and especially a low CD4 + T cell count [3] and the potential to infect CD4 + T cells [4]. It is generally assumed that the mortality is due to lung failure, but here we describe a patient who developed a strong inflammatory response with high C-reactive protein, very high IL-6 and white blood cells (WBC) and went into an irreversible metabolic acidosis.

Case report

A 72-year-old man with diabetes mellitus and G-6PD deficiency presented with 10-day history of fever, dry cough, shortness of breath and nasal congestion. At admission his oxygen saturation was 95 % on 3 L of oxygen. Hemoglobin concentration was 13.6 g/dL(normal range: 11.5–15.5), white blood cell count (WBC) of 4200/uL (normal range: 2200–10000), lymphocyte count of 700 /uL (normal range: 1200–4000), C-reactive protein of 152 mg/L (normal range: <10), alanine aminotransferase (ALT) of 61 IU/L (normal range 10–49), total bilirubin 1.87 mg/dL (normal range:0.1–1.2), renal function test was normal and chest radiograph revealed right lung ground glass opacities. Nasopharyngeal swab for SARS-CoV-2 RNA was positive. He was started on ceftriaxone 2 gm once daily and azithromycin 500 mg once daily according to national guidelines. On day 12 of his illness (2nd day after admission), his hypoxia worsened. Arterial blood gas showed a pH of 7.48, PaCO2 31 mmHg, PaO2 60 mmHg, bicarbonate 23 mmol/L, lactate 1.5 mmol/L and a C-reactive protein of 237 mg/L (Fig. 1A). He was intubated and started on mechanical ventilation. Hydroxychloroquine, beta interferon and lopinavir/ritonavir were added according to national guidelines. Post intubation, the patient was kept on volume-controlled ventilation and lung protective mode with a tidal volume of 6 mL/kg of predicative body weight (PBW) and positive end expiratory pressure (PEEP) between 16–18 cmH2O. The sedation was maintained with intravenous fentanyl and midazolam with additional intermittent doses of cisatracurium. CO2 accumulation was significant with a pCO2 of 70−80 mmHg. This was attributed to acute lung injury due to SARS-CoV2 and the use of protective lung ventilation strategy. Therefore PEEP was lowered and tidal volume raised. Fraction of inspired oxygen (FiO2) was also successfully weaned to 0.5 with targeted partial pressure of oxygen (PO2) above 60 mmHg.
Fig. 1

A) shows the trend of PaO2,PaO2/FiO2 ratio through the days of illness, B) shows the trend of pH, C) shows values of PCO2, D) shows the minimal followed by the sharp rise of lactate towards 7the end, E) shows the gradual rise in WBC as the disease progressed along, F) shows the rise and fall of CRP, G) shows the rise of interleukin-6, H) shows the trend of tumor necrosis factor alpha (TNFα) and I) shows the level interleukin-10(IL-10) measured.

A) shows the trend of PaO2,PaO2/FiO2 ratio through the days of illness, B) shows the trend of pH, C) shows values of PCO2, D) shows the minimal followed by the sharp rise of lactate towards 7the end, E) shows the gradual rise in WBC as the disease progressed along, F) shows the rise and fall of CRP, G) shows the rise of interleukin-6, H) shows the trend of tumor necrosis factor alpha (TNFα) and I) shows the level interleukin-10(IL-10) measured. By day 14 he had a worsening renal function with a GFR of 40 mL/min (normal range >90). The WBC had increased to 21100/uL, with 19700/uL neutrophils and persistent lymphopenia of 900 /uL. C-reactive protein doubled to 406 mg/L. He developed high grade fever and antimicrobials were changed to meropenem, levofloxacin and teicoplanin. He was initiated on continuous veno-venous hemodialysis (CVVHD). The possibility of a nosocomial infection versus cytokine storm was raised. By day 17 he showed significant improvement of his chest x-ray and ventilatory parameters reaching FiO2 of 0.45 and PEEP of 12 with PO2 more than 80 mmHg. His ABG showed pH 7.43, PaCO2 36 mmHg, PaO2 101 mmHg, bicarbonate of 24 mmol/L, lactate of 1.10 mmol/L. However, there was a further increase in WBC to 31500/uL with 26000/uL neutrophils with progressive drop in hemoglobin reaching 10.1 g/dL. Nasopharyngeal SARS-CoV-2 RNA on day 16 was still positive. Inspite of the initial improvement of ventilatory parameters, his pH was 7.28, PaO2 85 mmHg, PCO2 46 mmHg, HCO3− 22 mmol/L, Na 134 mmol/L,Cl 103 mmol/L, suggestive of metabolic acidosis with increased anion gap of 53mEq/L (normal range 8−16mEq/L), with further rise in WBC to 42900/uL and neutrophils to 34.8 × 109/L. The lactate dehydrogenase (LDH) was 2215 IU/L and haptoglobin less than 10 mg/L and a normal absolute reticulocyte count ruling out drug related hemolysis and suggesting on going cytokine storm. Over the next few days, the metabolic acidosis progressed despite CVVHD with pH of 6.9, PaO2 68 mmHg, PCO2 33 mmHg, Na 134 mmol/L, CL 102 mmol/L, lactate reaching 19.6 mmol/L, and the WBC increased to 59500/uL with neutrophils of 35000/u L, ALT increased to more than 3300 IU/L, and interleukin-6 level was 262.7 pg/mL (normal range < 16.4) eventually leading to cardiopulmonary arrest and death.

Discussion

IL-6 is a strong predictor of respiratory failure [5]. During the energy producing metabolism that takes place in the cytoplasm of cells, glucose is transformed into pyruvate molecules generating 2 ATP molecules. During this glycolysis process, no oxygen is utilized. If the tissue oxygenation is regular, pyruvate molecules enters the mitochondria where they undergoes a series of enzymatic processes generating ATP, as well as CO2 and H2O molecules. In a situation of tissue hypoxia pyruvate molecules cannot enter the mitochondria but are converted to lactic acid and in this process ATP is released maintaining the energy production. The lactic acid is removed mainly through the process of gluconeogenesis that takes place in the liver and kidney cortex, but also through the oxidation process in various organs. The lactic acid accumulation is the result of increased production and/or its decreased removal [6]. On 18th day of the patient’s illness, the lactic acid levels started to increase significantly but levels of pCO2 were acceptable, it was concluded that he was in metabolic acidosis. It is possible that dysregulated inflammatory response (cytokine storm) caused the metabolic acidosis.This has been described in severe bacterial sepsis [7]. Another reason could be extensive microvascular thrombosis causing the tissue hypoxia which has been described in COVID-19 patients [8]. Significant contribution to high lactic acid levels probably also comes from the high WBC count [9]. However, there is also the possibility of mitochondrial toxicity caused by lopinavir and ritonavir treatment although this is less likely to occur in short treatment duration [10].

Consent for publication

Consent to publish this case report was obtained from the patient’s family and the copy of the consent is available for the journal on request.

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Author’s contribution

Shabnam Chhetri: Writing (original draft preparation). Faryal Khamis: Conceptualization, Supervision, Writing (Review and editing). Eskild Peterson: Supervision, Writing (Review and editing). Nenad Pandak: Writing (Review and editing). Huda Al Khalili: Writing (Review and editing). Elias Said: Investigation (performing laboratory test). All authors read and approved the final manuscript.

Declaration of Competing Interest

All authors have no competing interests to declare.
  8 in total

1.  Lactic acidosis.

Authors:  Daniel De Backer
Journal:  Intensive Care Med       Date:  2003-04-08       Impact factor: 17.440

Review 2.  L-lactic acidosis: pathophysiology, classification, and causes; emphasis on biochemical and metabolic basis.

Authors:  Kamel S Kamel; Man S Oh; Mitchell L Halperin
Journal:  Kidney Int       Date:  2019-09-06       Impact factor: 10.612

3.  Hemoadsorption by CytoSorb in septic patients: a case series.

Authors:  Klaus Kogelmann; Dominik Jarczak; Morten Scheller; Matthias Drüner
Journal:  Crit Care       Date:  2017-03-27       Impact factor: 9.097

4.  [Characteristics, causes, diagnosis and treatment of coagulation dysfunction in patients with COVID-19].

Authors:  H Mei; Y Hu
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2020-03-14

5.  COVID-19 illness in native and immunosuppressed states: A clinical-therapeutic staging proposal.

Authors:  Hasan K Siddiqi; Mandeep R Mehra
Journal:  J Heart Lung Transplant       Date:  2020-03-20       Impact factor: 10.247

6.  Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19.

Authors:  Muthiah Vaduganathan; Orly Vardeny; Thomas Michel; John J V McMurray; Marc A Pfeffer; Scott D Solomon
Journal:  N Engl J Med       Date:  2020-03-30       Impact factor: 91.245

7.  Characteristics of Peripheral Lymphocyte Subset Alteration in COVID-19 Pneumonia.

Authors:  Fan Wang; Jiayan Nie; Haizhou Wang; Qiu Zhao; Yong Xiong; Liping Deng; Shihui Song; Zhiyong Ma; Pingzheng Mo; Yongxi Zhang
Journal:  J Infect Dis       Date:  2020-05-11       Impact factor: 5.226

8.  RETRACTED ARTICLE: SARS-CoV-2 infects T lymphocytes through its spike protein-mediated membrane fusion.

Authors:  Xinling Wang; Wei Xu; Gaowei Hu; Shuai Xia; Zhiping Sun; Zezhong Liu; Youhua Xie; Rong Zhang; Shibo Jiang; Lu Lu
Journal:  Cell Mol Immunol       Date:  2020-04-07       Impact factor: 11.530

  8 in total
  9 in total

Review 1.  The Lactate and the Lactate Dehydrogenase in Inflammatory Diseases and Major Risk Factors in COVID-19 Patients.

Authors:  G S Gupta
Journal:  Inflammation       Date:  2022-05-19       Impact factor: 4.657

2.  Predictors of COVID-19 severity: a systematic review and meta-analysis.

Authors:  Mudatsir Mudatsir; Jonny Karunia Fajar; Laksmi Wulandari; Gatot Soegiarto; Muhammad Ilmawan; Yeni Purnamasari; Bagus Aulia Mahdi; Galih Dwi Jayanto; Suhendra Suhendra; Yennie Ayu Setianingsih; Romi Hamdani; Daniel Alexander Suseno; Kartika Agustina; Hamdan Yuwafi Naim; Muchamad Muchlas; Hamid Hunaif Dhofi Alluza; Nikma Alfi Rosida; Mayasari Mayasari; Mustofa Mustofa; Adam Hartono; Richi Aditya; Firman Prastiwi; Fransiskus Xaverius Meku; Monika Sitio; Abdullah Azmy; Anita Surya Santoso; Radhitio Adi Nugroho; Camoya Gersom; Ali A Rabaan; Sri Masyeni; Firzan Nainu; Abram L Wagner; Kuldeep Dhama; Harapan Harapan
Journal:  F1000Res       Date:  2020-09-09

Review 3.  COVID-19: a new emerging respiratory disease from the neurological perspective.

Authors:  Amr El-Sayed; Lotfi Aleya; Mohamed Kamel
Journal:  Environ Sci Pollut Res Int       Date:  2021-02-15       Impact factor: 4.223

Review 4.  The contributory role of lymphocyte subsets, pathophysiology of lymphopenia and its implication as prognostic and therapeutic opportunity in COVID-19.

Authors:  Mahda Delshad; Naeimeh Tavakolinia; Atieh Pourbagheri-Sigaroodi; Ava Safaroghli-Azar; Nader Bagheri; Davood Bashash
Journal:  Int Immunopharmacol       Date:  2021-03-18       Impact factor: 5.714

Review 5.  Potential of Omega 3 Supplementation for Coronavirus Disease 2019 (COVID-19): A Scoping Review.

Authors:  Nanda Nursyifa Fadiyah; Ginna Megawati; Dimas Erlangga Luftimas
Journal:  Int J Gen Med       Date:  2022-04-11

6.  Acid base disorders in patients with COVID-19.

Authors:  Gaetano Alfano; Francesco Fontana; Giacomo Mori; Francesco Giaroni; Annachiara Ferrari; Silvia Giovanella; Giulia Ligabue; Elisabetta Ascione; Silvia Cazzato; Marco Ballestri; Margherita Di Gaetano; Marianna Meschiari; Marianna Menozzi; Jovana Milic; Bedini Andrea; Erica Franceschini; Gianluca Cuomo; Riccardo Magistroni; Cristina Mussini; Gianni Cappelli; Giovanni Guaraldi
Journal:  Int Urol Nephrol       Date:  2021-06-11       Impact factor: 2.370

7.  Validation of red cell distribution width as a COVID-19 severity screening tool.

Authors:  Mandana Pouladzadeh; Mehdi Safdarian; Parastoo Moradi Choghakabodi; Fatemeh Amini; Alireza Sokooti
Journal:  Future Sci OA       Date:  2021-04-20

Review 8.  CD38 in the age of COVID-19: a medical perspective.

Authors:  Alberto L Horenstein; Angelo C Faini; Fabio Malavasi
Journal:  Physiol Rev       Date:  2021-03-31       Impact factor: 37.312

Review 9.  Human placenta-derived amniotic epithelial cells as a new therapeutic hope for COVID-19-associated acute respiratory distress syndrome (ARDS) and systemic inflammation.

Authors:  Amirhesam Babajani; Kasra Moeinabadi-Bidgoli; Farnaz Niknejad; Hamidreza Rismanchi; Sepehr Shafiee; Siavash Shariatzadeh; Elham Jamshidi; Mohammad Hadi Farjoo; Hassan Niknejad
Journal:  Stem Cell Res Ther       Date:  2022-03-25       Impact factor: 6.832

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.